Preclinical studies in mouse myeloma models showed that targeting DKK-1 with neutralizing anti-DKK-1 antibodies increased osteoblasts, reduced multinucleated osteoclasts, and increased bone mass [122,123]. This evidence concerns the gene DKK1 and plasma cell myeloma.